Advanced glycation end products enhance monocyte activation during human mixed lymphocyte reaction

Clin Immunol. 2010 Mar;134(3):345-53. doi: 10.1016/j.clim.2009.10.008. Epub 2009 Nov 13.

Abstract

Posttransplant diabetes mellitus (PTDM) is a frequent complication among transplant recipients. Ligation of advanced glycation end products (AGEs) with their receptor (RAGE) on monocytes/macrophages plays roles in the diabetes complications. The enhancement of adhesion molecule expression on monocytes/macrophages activates T-cells, leading to reduced allograft survival. We investigated the effect of four distinct AGE subtypes (AGE-2/AGE-3/AGE-4/AGE-5) on the expressions of intracellular adhesion molecule (ICAM)-1, B7.1, B7.2 and CD40 on monocytes, the production of interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha and the proliferation of T-cells during human mixed lymphocyte reaction (MLR). AGE-2 and AGE-3 selectively induced the adhesion molecule expression, cytokine production and T-cell proliferation. The AGE-induced up-regulation of adhesion molecule expression was involved in the cytokine production and T-cell proliferation. AGE-2 and AGE-3 up-regulated the expression of RAGE on monocytes; therefore, the AGEs may activate monocytes, leading to the up-regulation of adhesion molecule expression, cytokine production and T-cell proliferation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Adhesion Molecules / immunology
  • Flow Cytometry
  • Glycation End Products, Advanced / immunology*
  • Humans
  • Kinetics
  • Lymphocyte Activation / immunology
  • Lymphocyte Culture Test, Mixed / methods
  • Monocytes / immunology*
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / immunology*

Substances

  • Cell Adhesion Molecules
  • Glycation End Products, Advanced
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic